L'iperparatiroidismo come fattore di rischio cardiovascolare nell'insufficienza renale

un update dal punto di vista biologico-cellulare.

Translated title of the contribution: [Hyperparathyroidism as a cardiovascular risk factor in chronic kidney disease: an update from a biological-cellular perspective].

Giuseppe Vezzoli, Teresa Arcidiacono, Francesco Rainone, Annalisa Terranegra, Andrea Aloia, Elena Dogliotti, Alessandra Mingione, Laura Soldati, Donatella Spotti

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Cardiovascular complications are the main cause of death in patients with chronic kidney disease (CKD). Among these complications, calcific arteriosclerosis and myocardial hypertrophy are the main predictors of cardiovascular morbidity and mortality. Epidemiological studies have shown their association with hyperparathyroidism, which has therefore been included among the non-traditional cardiovascular risk factors. Studies in laboratory animals have shown that PTH administration may induce calcific arteriosclerosis and myocardial hypertrophy. The former develops independently of hyperphosphatemia, but its mechanisms remain unknown. The latter is characterized by increased thickness of the myocardial fibers and especially the fibrous interstitium; its development is influenced by protein kinase C activation and the subsequent increase in cytosolic calcium as well as activation of intracellular signaling pathways inducing protein synthesis and proliferation. Different from these findings, in other studies PTH infusion was able to produce vasodilatation and to favor myocardial cell contraction and regeneration. These effects depend on protein kinase A activation. PTH may produce different and sometimes contradictory functional effects in the arteries and myocardium that are probably related to different experimental or clinical conditions. In patients with CKD and hyperparathyroidism, PTH may be considered a uremic toxin exerting its effects mainly by increasing cellular calcium. Thus, hyperparathyroidism is confirmed to be a target for the conservative therapy of CKD.

Original languageItalian
Pages (from-to)383-392
Number of pages10
JournalGiornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia
Volume28
Issue number4
Publication statusPublished - Jul 2011
Externally publishedYes

Fingerprint

Hyperparathyroidism
Chronic Renal Insufficiency
Arteriosclerosis
Hypertrophy
Calcium
Myocardial Contraction
Hyperphosphatemia
Laboratory Animals
Cyclic AMP-Dependent Protein Kinases
Vasodilation
Protein Kinase C
Epidemiologic Studies
Regeneration
Cause of Death
Myocardium
Arteries
Morbidity
Mortality
Proteins

ASJC Scopus subject areas

  • Nephrology

Cite this

L'iperparatiroidismo come fattore di rischio cardiovascolare nell'insufficienza renale : un update dal punto di vista biologico-cellulare. / Vezzoli, Giuseppe; Arcidiacono, Teresa; Rainone, Francesco; Terranegra, Annalisa; Aloia, Andrea; Dogliotti, Elena; Mingione, Alessandra; Soldati, Laura; Spotti, Donatella.

In: Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia, Vol. 28, No. 4, 07.2011, p. 383-392.

Research output: Contribution to journalReview article

Vezzoli, Giuseppe ; Arcidiacono, Teresa ; Rainone, Francesco ; Terranegra, Annalisa ; Aloia, Andrea ; Dogliotti, Elena ; Mingione, Alessandra ; Soldati, Laura ; Spotti, Donatella. / L'iperparatiroidismo come fattore di rischio cardiovascolare nell'insufficienza renale : un update dal punto di vista biologico-cellulare. In: Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia. 2011 ; Vol. 28, No. 4. pp. 383-392.
@article{e1adbee2d88f46a5b8af606efac1a423,
title = "L'iperparatiroidismo come fattore di rischio cardiovascolare nell'insufficienza renale: un update dal punto di vista biologico-cellulare.",
abstract = "Cardiovascular complications are the main cause of death in patients with chronic kidney disease (CKD). Among these complications, calcific arteriosclerosis and myocardial hypertrophy are the main predictors of cardiovascular morbidity and mortality. Epidemiological studies have shown their association with hyperparathyroidism, which has therefore been included among the non-traditional cardiovascular risk factors. Studies in laboratory animals have shown that PTH administration may induce calcific arteriosclerosis and myocardial hypertrophy. The former develops independently of hyperphosphatemia, but its mechanisms remain unknown. The latter is characterized by increased thickness of the myocardial fibers and especially the fibrous interstitium; its development is influenced by protein kinase C activation and the subsequent increase in cytosolic calcium as well as activation of intracellular signaling pathways inducing protein synthesis and proliferation. Different from these findings, in other studies PTH infusion was able to produce vasodilatation and to favor myocardial cell contraction and regeneration. These effects depend on protein kinase A activation. PTH may produce different and sometimes contradictory functional effects in the arteries and myocardium that are probably related to different experimental or clinical conditions. In patients with CKD and hyperparathyroidism, PTH may be considered a uremic toxin exerting its effects mainly by increasing cellular calcium. Thus, hyperparathyroidism is confirmed to be a target for the conservative therapy of CKD.",
author = "Giuseppe Vezzoli and Teresa Arcidiacono and Francesco Rainone and Annalisa Terranegra and Andrea Aloia and Elena Dogliotti and Alessandra Mingione and Laura Soldati and Donatella Spotti",
year = "2011",
month = "7",
language = "Italian",
volume = "28",
pages = "383--392",
journal = "Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia",
issn = "0393-5590",
publisher = "Wichtig Publishing",
number = "4",

}

TY - JOUR

T1 - L'iperparatiroidismo come fattore di rischio cardiovascolare nell'insufficienza renale

T2 - un update dal punto di vista biologico-cellulare.

AU - Vezzoli, Giuseppe

AU - Arcidiacono, Teresa

AU - Rainone, Francesco

AU - Terranegra, Annalisa

AU - Aloia, Andrea

AU - Dogliotti, Elena

AU - Mingione, Alessandra

AU - Soldati, Laura

AU - Spotti, Donatella

PY - 2011/7

Y1 - 2011/7

N2 - Cardiovascular complications are the main cause of death in patients with chronic kidney disease (CKD). Among these complications, calcific arteriosclerosis and myocardial hypertrophy are the main predictors of cardiovascular morbidity and mortality. Epidemiological studies have shown their association with hyperparathyroidism, which has therefore been included among the non-traditional cardiovascular risk factors. Studies in laboratory animals have shown that PTH administration may induce calcific arteriosclerosis and myocardial hypertrophy. The former develops independently of hyperphosphatemia, but its mechanisms remain unknown. The latter is characterized by increased thickness of the myocardial fibers and especially the fibrous interstitium; its development is influenced by protein kinase C activation and the subsequent increase in cytosolic calcium as well as activation of intracellular signaling pathways inducing protein synthesis and proliferation. Different from these findings, in other studies PTH infusion was able to produce vasodilatation and to favor myocardial cell contraction and regeneration. These effects depend on protein kinase A activation. PTH may produce different and sometimes contradictory functional effects in the arteries and myocardium that are probably related to different experimental or clinical conditions. In patients with CKD and hyperparathyroidism, PTH may be considered a uremic toxin exerting its effects mainly by increasing cellular calcium. Thus, hyperparathyroidism is confirmed to be a target for the conservative therapy of CKD.

AB - Cardiovascular complications are the main cause of death in patients with chronic kidney disease (CKD). Among these complications, calcific arteriosclerosis and myocardial hypertrophy are the main predictors of cardiovascular morbidity and mortality. Epidemiological studies have shown their association with hyperparathyroidism, which has therefore been included among the non-traditional cardiovascular risk factors. Studies in laboratory animals have shown that PTH administration may induce calcific arteriosclerosis and myocardial hypertrophy. The former develops independently of hyperphosphatemia, but its mechanisms remain unknown. The latter is characterized by increased thickness of the myocardial fibers and especially the fibrous interstitium; its development is influenced by protein kinase C activation and the subsequent increase in cytosolic calcium as well as activation of intracellular signaling pathways inducing protein synthesis and proliferation. Different from these findings, in other studies PTH infusion was able to produce vasodilatation and to favor myocardial cell contraction and regeneration. These effects depend on protein kinase A activation. PTH may produce different and sometimes contradictory functional effects in the arteries and myocardium that are probably related to different experimental or clinical conditions. In patients with CKD and hyperparathyroidism, PTH may be considered a uremic toxin exerting its effects mainly by increasing cellular calcium. Thus, hyperparathyroidism is confirmed to be a target for the conservative therapy of CKD.

UR - http://www.scopus.com/inward/record.url?scp=84856393785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856393785&partnerID=8YFLogxK

M3 - Review article

VL - 28

SP - 383

EP - 392

JO - Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia

JF - Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia

SN - 0393-5590

IS - 4

ER -